Mayo Advancing Research Equity in ADRD Study in Jacksonville(MAREAS-Jax)

梅奥在杰克逊维尔推进 ADRD 研究中的研究公平性 (MAREAS-Jax)

• 批准号: 10729787
• 负责人: Minerva Maria Carrasquillo
• 金额: $ 54.78万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-15 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10729787
• 关键词: Address; Advisory Committees; African American population; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; American; Amyloid; Amyloid beta-42; Biological; Biological Factors; Biological Markers; Blood; Blood Vessels; Brain; Censuses; Clinic; Clinical; Cognitive; Committee Members; Communication; Communities; Community Participation; DNA; Data; Data Collection; Dementia; Development; Disease; Disparate; Education; Equity; Evaluation; Exposure to; FAIR principles; Feedback; Florida; Focus Groups; Genetic; Genomics; Glial Fibrillary Acidic Protein; Goals; Guidelines; Health; Health behavior; High Prevalence; Hispanic; Hispanic Populations; Individual; Infrastructure; Institution; Investments; Knowledge; Latino; Latino Population; Life Style; Light; Link; Longevity; Measurable; Measures; Medical; Modification; Molecular; Molecular Profiling; Molecular Target; Multiomic Data; Nerve Degeneration; Not Hispanic or Latino; Outcome; Participant; Phase; Plasma; Policies; Population; Positron-Emission Tomography; RNA; Recommendation; Reporting; Research; Research Personnel; Risk; Risk Factors; Risk Reduction; Sampling; Social Environment; Social Processes; Standardization; Systems Biology; Time; United States; United States National Institutes of Health; bilingualism; biomarker identification; biomarker signature; blood-based biomarker; brain health; burden of illness; caucasian American; cerebrovascular; cohort; comorbidity; data analysis pipeline; data sharing; dementia risk; design; disparity elimination; disparity reduction; empowerment; health determinants; health disparity; imaging biomarker; improved; individualized feedback; infrastructure development; modifiable risk; multiple omics; neurofilament; neuroimaging; novel; outreach; personalized strategies; pre-clinical; programs; recruit; risk mitigation; social; social health determinants; tau Proteins

PROJECT SUMMARY/ABSTRACT Hispanics/Latinos (HL) and African Americans (AA) represent a rapidly growing proportion of the United States population (18.7% HL, 12.4% AA - US 2020 Census) who remain critically underrepresented in research of Alzheimer disease (AD) and AD-related dementia (ADRD), despite a 1.5-2-fold higher prevalence of dementia (vs non-Hispanic-white Americans). Underrepresentation in AD/ADRD research exacerbates health disparities and challenges the development and implementation of efficacious and safe risk-reduction strategies for AD/ADRD in HL/AA. Genetics do not fully explain disparate AD/ADRD risk, highlighting a fundamental knowledge gap concerning how genomic factors interact with comorbidities and lifespan exposures to Structural/Social Determinants of Health (SDoH; the “exposome”) to inform AD/ADRD risk. There is a critical need to identify clinical, SDoH, and biological factors that contribute to disparate risk in HL/AA; establish the relationship between exposures underlying AD/ADRD outcomes; use this information to mitigate disparities in AD/ADRD burden through education and risk factor modification; and broadly disseminate this information to inform the development of effective biomarkers and therapies. The Mayo Advancing Research Equity in ADRD Study in Jacksonville (MAREAS-JAX; Spanish for tides) will address this need. Aim 1 will advance recruitment of HL/AA cohorts (UH2) by developing/deploying outreach, recruitment, and engagement best practices for HL/AA in Jacksonville, Florida, through a bilingual (English-Spanish) research team, supported by community ambassador teams (CAT) and an external advisory committee (EAC) including experts in SDoH and AD/ADRD research. Aim 2 will identify relevant measures of AD/ADRD burden (UH2►UH3). SDoH, cognitive, clinical, and blood-based biomarker measures associated with cerebrovascular, amyloid, and tau burden, will be collected through comprehensive/culturally appropriate annual assessments and integrated with multi-omics data, structural (MR) and molecular (amyloid and tau) PET neuroimaging obtained at study entry, and every 2 years thereafter to identify modifiable dementia risk factors, blood-based biomarkers, and molecular signatures of AD/ADRD burden. Data collection will be standardized with input from EAC members to optimize scalability and promote sample/data sharing. Aim 3 will provide meaningful individualized feedback (UH3) to participants through a Brain Health Report detailing actionable risk factors and recommendations to mitigate intraindividual AD/ADRD burden. Aim 4 will use multi-omics measures to identify molecular targets and signatures that interact with the exposome and associate with AD/ADRD burden in HL/AA (UH3) using a systems biology approach with validated analytic pipelines and prioritizing broad data sharing following NIH’s findability, accessibility, interoperability, and reusability guidelines. In this way, MAREAS-Jax will chart the currents that drive disproportionate participation in AD/ADRD research and disparate AD/ADRD burden and will inform the design and implementation of strategies to shift these tides in Northeast Florida and beyond.

项目概要/摘要 西班牙裔/拉丁裔 (HL) 和非裔美国人 (AA) 在美国所占比例快速增长 人口（18.7％ HL，12.4％ AA - 美国 2020 年人口普查）在研究中的代表性仍然严重不足 阿尔茨海默病 (AD) 和 AD 相关痴呆 (ADRD)，尽管痴呆患病率高出 1.5-2 倍 （与非西班牙裔白人美国人相比）。 AD/ADRD 研究代表性不足加剧了健康差距 并挑战制定和实施有效和安全的风险降低战略 HL/AA 中的 AD/ADRD。遗传学并不能完全解释不同的 AD/ADRD 风险，突显了一个根本原因 关于基因组因素如何与合并症和寿命暴露相互作用的知识差距 健康的结构/社会决定因素（SDoH；“暴露组”）告知 AD/ADRD 风险。有一个关键的 需要确定导致 HL/AA 不同风险的临床、SDoH 和生物因素；建立 AD/ADRD 结果的暴露之间的关系；使用此信息来减少差异 通过教育和危险因素改变来减轻 AD/ADRD 负担；并将此信息广泛传播给 为有效生物标志物和疗法的开发提供信息。梅奥推进 ADRD 的研究股权 杰克逊维尔的研究（MAREAS-JAX；西班牙语潮汐）将满足这一需求。目标1将推进招募 通过开发/部署外展、招聘和参与最佳实践来扩大 HL/AA 群体 (UH2) HL/AA 在佛罗里达州杰克逊维尔，通过双语（英语-西班牙语）研究团队在社区的支持下进行 大使团队 (CAT) 和外部咨询委员会 (EAC)，其中包括 SDoH 和 AD/ADRD 方面的专家 研究。目标 2 将确定 AD/ADRD 负担的相关措施 (UH2►UH3)。 SDoH、认知、临床和 将收集与脑血管、淀粉样蛋白和 tau 负荷相关的血液生物标志物测量 通过全面/适合文化的年度评估并与多组学数据相结合， 在研究开始时以及每两年获得一次结构 (MR) 和分子（淀粉样蛋白和 tau）PET 神经影像 此后确定可改变的痴呆症危险因素、血液生物标志物和分子特征 AD/ADRD 负担。数据收集将根据 EAC 成员的意见进行标准化，以优化可扩展性和 促进样本/数据共享。目标 3 将为参与者提供有意义的个性化反馈 (UH3) 通过大脑健康报告，详细说明可采取行动的风险因素和减轻个体内部风险的建议 AD/ADRD 负担。目标 4 将使用多组学措施来识别相互作用的分子靶点和特征 使用系统生物学方法与暴露组相关，并与 HL/AA (UH3) 中的 AD/ADRD 负担相关联 验证分析流程并根据 NIH 的可查找性、可访问性优先考虑广泛的数据共享， 互操作性和可重用性指南。通过这种方式，MAREAS-Jax 将绘制驱动电流的图表 不成比例地参与 AD/ADRD 研究和不同的 AD/ADRD 负担，并将为设计提供信息 并实施战略以扭转佛罗里达州东北部及其他地区的潮流。